METASTATIC MELANOMA

This study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. The goal was to see if the drug could shrink tumors and to study biological markers linked to response or resistance. Ibrutinib works by blocking certain e…

This study tests a combination of two treatments—heat-based tumor destruction (thermal ablation) and precise high-dose radiation (stereotactic radiosurgery)—for people whose cancer has spread to the spine and is pressing on the spinal cord. The goal is to control the tumor and pr…

This early-phase study tests whether adding a drug called rigosertib to the immunotherapy pembrolizumab can help people with advanced melanoma that no longer responds to standard immunotherapy. The trial enrolled only 7 adults with melanoma that had spread or couldn't be removed.…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…

This study tests a personalized cell therapy called lifileucel (TIL) for people with advanced melanoma that has not responded to standard treatments. About 100 adults with stage III or IV melanoma will receive their own immune cells that have been specially grown in a lab to figh…

This study tested two different sequences of powerful drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if …

This study tested a combination of three drugs—pembrolizumab (Keytruda), trametinib (Mekinist), and dabrafenib (Tafinlar)—in 16 people with advanced melanoma that could not be removed by surgery. The goal was to see if a shorter course of targeted therapy plus immunotherapy could…

This early-phase trial tested a combination of two drugs (cediranib and selumetinib) in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the drugs worked together. Cediranib cuts off blo…

This study looks at whether a focused radiation treatment called stereotactic radiosurgery (SRS) can control melanoma that has spread to more than 3 areas in the brain while also protecting memory and thinking skills. About 49 adults with advanced melanoma and multiple brain tumo…

This study looks at whether giving only 2 doses of the immunotherapy combination (ipilimumab + nivolumab) is enough for patients with advanced melanoma who show early benefit. If not, they can receive more doses, even beyond the usual 4. The goal is to personalize treatment and r…

This study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …

This study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma that has spread or cannot be removed by surgery, and in other solid tumors. The goal is to find the best dose and see how well the drugs shrink tumors. About…

This study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The trial involves 29 adults with untreated brain metastases and aims to s…

This early-phase study tests a personalized vaccine (NeoVax) combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab) in 10 people with advanced melanoma. The goal is to find the safest dose and see if the vaccine can boost the immun…

This study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…

This study tests two different three-drug combinations in people with advanced melanoma that has spread or can't be removed by surgery. The drugs include immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinations w…

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in 20 people with advanced melanoma that could not be surgically removed. The mai…

This early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…

This study tests whether combining an experimental drug (GSK2636771) with an approved immunotherapy (pembrolizumab) can help control metastatic melanoma in people whose tumors have a specific genetic change called PTEN loss. About 27 participants with advanced melanoma that hasn'…

This early-stage trial tests a new approach for people with advanced melanoma that has not responded to other treatments. It combines a specially designed virus (TILT-123) that targets cancer cells, chemotherapy, and the patient's own immune cells grown in a lab. The main goal is…

This study tests whether adding an experimental drug (tazemetostat) to two standard targeted therapies (dabrafenib and trametinib) can help people with advanced BRAF-mutated melanoma whose cancer has stopped responding to the standard drugs. About 16 adults with metastatic melano…

This study tests a combination of three treatments—an immune-boosting drug injected into a tumor (IL-2), targeted radiation, and the immunotherapy pembrolizumab—in adults with advanced lung, skin, kidney, or head-and-neck cancers that no longer respond to standard immunotherapy. …

This study compares two treatments for metastatic melanoma that has spread: high-dose immunotherapy (IL-2) alone versus the same immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better. 44 adults with up to 3 tumors that can…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests an inhaled form of a protein called interleukin-2 (IL-2) to treat cancers that have spread to the lungs, such as melanoma, kidney cancer, and sarcoma. The goal is to find the safest dose and see if it can shrink tumors. About 70 adults with advanced cancer and lu…

This early-phase study tests a new treatment called OBX-115, which uses a patient's own tumor-fighting immune cells that have been modified in the lab to include a protein (IL15) to help them survive longer. These cells are given along with acetazolamide to adults with metastatic…

This early-phase trial tests whether a personalized cell therapy called lifileucel (LN-144) can be safely given to people with melanoma that has spread to the brain. Participants must have tumors that can be surgically removed to harvest immune cells, which are then multiplied in…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…

This study was designed to test a device (NovoTTF-200A) combined with the immunotherapy drug pembrolizumab in people with melanoma that had spread to the brain. The goal was to see if the combination was safe and effective. However, the study was withdrawn before enrolling any pa…

This early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study is testing whether eating a high-fiber diet can change gut bacteria and improve the immune system's response to immunotherapy in people with advanced melanoma. Fifty patients starting standard immunotherapy will be randomly assigned to eat either a high-fiber diet or a…

This study is testing if adding an anti-inflammatory drug called infliximab to standard immunotherapy helps people with advanced melanoma. The goal is to see if this combination can better control the cancer while also reducing the severe digestive side effects that immunotherapy…